A carregar...
Enarodustat, Conversion and Maintenance Therapy for Anemia in Hemodialysis Patients: A Randomized, Placebo-Controlled Phase 2b Trial Followed by Long-Term Trial
BACKGROUND: Enarodustat (JTZ-951) is an orally available hypoxia-inducible factor prolyl hydroxylase inhibitor that increases endogenous erythropoietin levels in the treatment of anemia associated with chronic kidney disease (CKD). OBJECTIVE: A phase 2b study of enarodustat to assess the hemoglobin...
Na minha lista:
| Publicado no: | Nephron Clin Pract |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
S. Karger AG
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6878752/ https://ncbi.nlm.nih.gov/pubmed/31117088 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000500487 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|